A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

NCT06672978 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Pyelonephritis
Complicated Urinary Tract Infection

Interventions

DRUG: Meropenem-Vaborbactam
DRUG: Antibiotics

Sponsor

Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)

Collaborators

[object Object]